Products & ReviewDrug discovery > Pre-Clinical Development
Syngeneic Models
Accelerate the development of your immuno-oncology drugs with Crown Bioscience’s large panel of immunocompetent syngeneic models.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Description
Purpose: These models offer the immune functionality needed to evaluate efficacy, mechanism of action, and combination strategies for today’s most innovative immunotherapies.
Features or Benefits:
- Full checkpoint inhibitor benchmarking and baseline immune profiling
- Bioluminescent orthotopic and metastatic models for real-time tracking
- Full access to MuBase®, our searchable syngeneic model database
- RNA-seq and NGS data with mutational and transcriptomic insights
- Microbiome analysis tools to assess therapy responders vs. non-responders
- Combination therapy testing, including with ICD inducers and chemotherapy
- Immune cell profiling via validated FACS and IHC platforms
- Confident model selection using curated immuno-profiling, efficacy, and genetic data
- Faster study design and execution with pre-profiled, readily available models
- Predict clinical outcomes by mirroring immune response variability and resistance
Applications:
- Evaluate checkpoint inhibitors (anti-PD-1, PD-L1, CTLA-4) and combination strategies
- Study vaccine, bacterial, and viral immunotherapies
- Model tumor-immune interactions in subcutaneous, orthotopic, and metastatic settings
- Use for biomarker discovery, immunomodulatory profiling, and T cell infiltration studies
- Fast-track IO candidates with large-scale in vivo screening
- Explore microbiome–therapy interactions using fecal sequencing and analysisry, and mechanism-of-action studies
